# US 8,772,455 B2 · Markers for identifying tumor cells, methods and kit thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,455 B2
- Document ID: US8772455B2
- Status: Granted
- Kind: B2
- Application number: 13/431,919
- Filed: 2012-03-27
- Published: 2012-09-27
- Granted: 2014-07-08
- Earliest claimed: 2011-03-27
- Assignees: Oncostem Diagnostics (Mauritius) Pvt. Ltd.
- Applicants: Manjiri Bakre
- Inventors: Manjiri Bakre
- Web page: https://patentgrep.com/patent/US8772455B2

## CPC

- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- G01N 33/575: for cancer
- G01N 33/57515: of the breast
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer. The present disclosure further relates to a kit/test comprising the antibodies against/other methods of detecting said markers for the said prediction.

## Claims

### Claim 1

A combination of
biological markers consisting of CD44, ABCC4, P-cadherin and β-catenine
for prognosis of breast cancer or recurrence of breast cancer, based on the estrogen receptor and progesterone receptor status.

### Claim 2 (depends on 1)

The combination of claim 1, wherein the markers are located on breast cancer cells of a subject at locations selected from a group comprising cell membrane, cytoplasm, nucleus, and nuclear membrane or any combination thereof.

### Claim 3 (depends on 1)

The combination of claim 1, further comprising one or more biological markers ABCG2, CD133, and/or Oct-4.